Want to see TRVI full AI Analyst Report?
TRVI Stock Chart & Stats
$13.47
<$0.01(0.12%)
At close: 4:00 PM EST
$13.47
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$6.93 - $20.22
Previous CloseN/A
Volume226.18K
Average Volume (3M)2.56M
Market Cap
$2.68B
Enterprise Value$2.60K
Total Cash (Recent Filing)$318.87M
Total Debt (Recent Filing)$605.00K
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding142,475,850
10 Day Avg. Volume1,820,513
30 Day Avg. Volume2,561,308
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)9.91
Price to Sales (P/S)0.00
P/FCF Ratio-43.15
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.08
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.00Price Target Upside115.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Cash Runway Into 2030A pro forma cash position of ~ $334M and guidance that financing extends runway into 2030 materially reduces near-term financing pressure and enables concurrent pivotal programs. This durable liquidity supports multi‑trial execution, decreases immediate dilution risk and buys time for regulatory readouts or partnership discussions.
Low Leverage And Stronger Equity BaseVery low leverage and a materially larger equity base improve financial flexibility for a pre‑revenue biotech. This structural strength enables Trevi to fund development via equity or partner deals, supports borrowing capacity if needed, and reduces insolvency risk during multi-year clinical programs.
Issued Patents Protecting Lead ProgramIssued core patents across major jurisdictions provide durable exclusivity for Haduvio in IPF-related chronic cough, underpinning long-term commercial value if approved. Ongoing prosecution to extend protection and label-enablement filings can meaningfully improve bargaining power with partners and protect pricing over a multi-year launch horizon.
Bears Say
Pre-revenue With Persistent Cash BurnAs a clinical‑stage company with no product revenue and sustained operating cash outflows, Trevi remains dependent on external financing or partnerships. Even with current runway, continued negative cash flow means future dilution or debt is likely if clinical timelines or costs extend, affecting long-term capital structure and strategic options.
Competitive Uncertainty From P2X3 ReadoutsCompetitor P2X3 trial outcomes are a structural industry risk: positive P2X3 efficacy or tolerability results could erode Trevi's differentiated positioning, impact payer willingness and limit commercial uptake. This external scientific risk affects long-term revenue potential and partner interest regardless of Trevi's trial execution.
Trial Upsizing & Regulatory Contingency RiskAdaptive designs and SSRE clauses create durable execution risk: conditional power shortfalls can force larger sample sizes, longer timelines and higher spend. Separately, programs contingent on FDA alignment may be delayed or altered, increasing funding needs and complicating long‑term planning for commercialization and partnerships.
Trevi Therapeutics News
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $6.93 and its highest was $20.22 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $2.68B.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Nov 11, 2026 which is in 81 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.109 by -$0.001.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.13.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 142,475,850 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.109. Following the earnings report the stock price went up 0.054%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trevi Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.00 (115.29% Upside)
$29.00 (115.29% Upside)
Hedge Fund Trend
Increased
By 326.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
232.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
58.64%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
TRVI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid execution progress: a strengthened balance sheet (pro forma cash ~ $334M) with runway into 2030, positive FDA alignment for IPF-related chronic cough, near-term trial initiations (Phase III IPF, Phase IIb RCC), an adaptive plan for non-IPF-ILD pending FDA agreement, expansion of IP filings and active scientific visibility (ATS, Investor Day). Principal risks discussed include competitor P2X3 readouts, possible trial upsizing via SSRE (and associated costs/timing), placebo variability in RCC, and regulatory dependence for the non-IPF-ILD program. On balance, the company presented multiple material positives and manageable risks tied to execution and external competitive/regulatory factors.View all TRVI earnings summariesTRVI Stock 12 Month Forecast
Average Price Target
$29.00
▲(115.29% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
1.31% Insiders
16.75% Mutual Funds
56.57% Other Institutional Investors
14.98% Public Companies and
Individual Investors